Triptolide attenuates proteinuria and podocyte apoptosis via inhibition of NF-κB/ GADD45B

Ling Wang,Liwen Zhang,Qing Hou,Xiaodong Zhu,Zhaohong Chen,Zhihong Liu

DOI: https://doi.org/10.1038/s41598-018-29203-1

IF: 4.6

2018-01-01

Scientific Reports

Abstract:Podocyte injury is a primary contributor to proteinuria. Triptolide is a major active component of Tripterygium wilfordii Hook F that exhibits potent antiproteinuric effects. We used our previously developed in vivo zebrafish model of inducible podocyte-target injury and found that triptolide treatment effectively alleviated oedema, proteinuria and foot process effacement. Triptolide also inhibited podocyte apoptosis in our zebrafish model and in vitro . We also examined the mechanism of triptolide protection of podocyte. Whole-genome expression profiles of cultured podocytes demonstrated that triptolide treatment downregulated apoptosis pathway-related GADD45B expression. Specific overexpression of gadd45b in zebrafish podocytes abolished the protective effects of triptolide. GADD45B is a mediator of podocyte apoptosis that contains typical NF-κB binding sites in the promoter region, and NF-κB p65 primarily transactivates this gene. Triptolide inhibited NF-κB signalling activation and binding of NF-κB to the GADD45B promoter. Taken together, our findings demonstrated that triptolide attenuated proteinuria and podocyte apoptosis via inhibition of NF-κB/ GADD45B signalling, which provides a new understanding of the antiproteinuric effects of triptolide in glomerular diseases.